Wall Road will see a holiday-shortened week on account of the Labor Day weekend. Nonetheless, buyers could have loads to digest, with the spotlight being Friday’s August nonfarm payrolls report.
The labor market will likely be squarely in focus, with updates on job openings and personal sector employment scheduled for Wednesday and Thursday. The large occasion will likely be on Friday, particularly after July’s nonfarm payrolls got here in considerably weaker than anticipated and Might and June noticed one of many largest two-month revisions to job development in many years. Any additional indicators of weakening within the U.S. labor state of affairs will all however assure a Federal Reserve price reduce in September for merchants.
Some quarterly earnings reviews from main tech names may also seize the highlight this week, particularly Dow 30 element Salesforce (CRM) and chipmaker Broadcom (AVGO).
Investing Group Highlight
Samuel Smith launched Excessive Yield Investor again in 2020 on the idea that buyers shouldn’t want to decide on between earnings and development when constructing a dividend-focused portfolio. Excessive Yield Investor’s three portfolios—Core, Worldwide and Retirement—are designed with precisely this stability in thoughts.
A West Level graduate, Samuel heads up an All-Star group that features Jussi Askola and Paul R. Drake. Collectively, they stability security, development, yield, and worth whereas providing deep-dive evaluation, real-money portfolios, commerce alerts, academic sources, and an lively chat room for engaged, like-minded buyers.
Two of Samuel’s present high concepts:
AbbVie (ABBV) (free write-up) stays a powerful dividend-growth inventory regardless of challenges from declining Humira gross sales following its patent expiry. The corporate is shifting focus to Skyrizi and Rinvoq, each exhibiting sturdy development and lengthy patent safety, whereas additionally investing in neuroscience, acquisitions, and improvement tasks. Q2 outcomes had been stable, with rising income and earnings, although aesthetics gross sales declined. Analysts venture 11% EPS CAGR by means of 2029. Dangers embody excessive valuation, U.S. coverage pressures, debt from Allergan, and Humira erosion. Whereas dividends seem secure, ABBV carries uncertainties. General, AbbVie is engaging long run, however present valuation warrants warning.
ONEOK (OKE) (free write-up) shares have fallen sharply, creating what seems to be a compelling shopping for alternative for long-term, income-focused buyers. Whereas 2026 steerage was trimmed attributable to weaker commodity costs, OKE continues to publish sturdy development, pushed largely by pure gasoline and NGL operations. Administration reaffirmed 2025 EBITDA steerage, highlighted $1.3 billion in tax advantages, and is investing in tasks just like the Medford enlargement and Texas Metropolis export terminal. With 11 years of EBITDA development, a 5.7% dividend yield, low leverage, and a reduced valuation versus friends, OKE affords engaging risk-reward regardless of commodity and venture dangers.
Samuel has been including closely to those names at Excessive Yield Investor, which is now providing a limited-time 20% introductory low cost for first-time subscribers.
Earnings highlight: Tuesday, September 2: Zscaler (ZS), Signet Jewelers (SIG). See the total earnings calendar.
Earnings highlight: Wednesday, September 3: Salesforce (CRM), Figma (FIG), Hewlett Packard (HPE), Greenback Tree (DLTR), Macy’s (M). See the total earnings calendar.
Earnings highlight: Thursday, September 4: Broadcom (AVGO), lululemon athletica (LULU), DocuSign (DOCU). See the total earnings calendar.
